Findings from GlaxoSmithKline plc Provides New Data about Asthma (Burden of Illness and Costs Associated With Eosinophilic Granulomatosis With Polyangiitis: Evidence From a Managed Care Database In the United States): Lung Diseases and Conditions – Asthma

2021 OCT 12 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- Investigators publish new report on Lung Diseases and Conditions - Asthma. According to news reporting out of Research Triangle Park, North Carolina, by NewsRx editors, research stated, “Data on the clinical and economic burden of eosinophilic granulomatosis with polyangiitis (EGPA) are limited. To assess the real-world clinical and economic outcomes of patients diagnosed with EGPA vs patients with asthma (present in >90% of EGPA cases) receiving treatment in the United States.”

Financial support for this research came from GlaxoSmithKline.

Our news journalists obtained a quote from the research from GlaxoSmithKline plc, “This retrospective cohort study (HO-17-17742) used administrative claims data (July 1, 2007-May 31, 2017) from the Optum Research Database. Eligible patients were aged at least 18 years at index (first date that patients met the EGPA or asthma cohort definition), with a minimum of 6 months of continuous health plan coverage before the index (baseline) period and 12 months following and including the index date (follow-up period). Patients with EGPA were identified either via published algorithms using claim code combinations for conditions and medications (before October 1, 2015) or via a claim with the EGPA ICD-10-CM code (M30.1, after October 1, 2015). Patients with asthma were identified based on ICD-9-CM and ICD-10-CM diagnosis codes and at least 3 pharmacy asthma-related medication claims within a year of diagnosis. Outcomes included all-cause health care costs (primary), all-cause health care resource utilization (HCRU), systemic corticosteroid (SCS) use, and EGPA relapses requiring hospitalization and EGPA-related (based on EGPA-related HCRU) relapses during the follow-up period (all secondary). EGPA and asthma cohorts were matched (1:3) via propensity score matching based on demographic, insurance, and index timing covariates. 8,904 patients were included in the matched EGPA (n = 2,226) and asthma (n = 6,678) cohorts (mean [SD] age: 59.7 [14.2] vs 59.6 [14.7] years; Quan-Charlson Comorbidity Index scores: 1.8 [1.7] vs 0.8 [1.4]). During follow-up, mean (SD) all-cause costs ($49,593 [$88,161] vs S21,122 [$40,110]; P<0.001), all-cause HCRU (P <0.001), and the proportion of patients with 1 or more SCS claims (72.3% vs 66.9%; P<0.001) were significantly greater in the EGPA vs asthma cohorts, respectively. Mean daily SCS dose (43.6-45.5 mg/day) was similar between cohorts; patients with EGPA had significantly (P <0.001) longer periods taking SCS doses at least 4 mg/day (mean [SD]: 64.9 [95.6] vs 14.6 [39.3] days) and at least 7 mg/day (52.8 [82.0] vs 12.1 [30.6] days). 35.2% (n = 784/2,226) and 44.1% (n = 981/2,226) of patients with EGPA experienced a minimum of 1 EGPA relapse requiring hospitalization, and at least 1 EGPA-related relapse, respectively. Mean (SD) total all-cause costs were greater than 3-fold higher in patients with vs without a relapse requiring hospitalization ($92,825 [$128,562] vs $26,087 [$38,082]; P<0.001) and for patients with vs without an EGPArelated relapse ($78,081 [$120,775] vs $27,145 [$35,584]; P<0.001). Patients with EGPA have more comorbidities, greater health care costs and HCRU, and use SCS more frequently than patients with asthma. Additionally, more than one third of patients with EGPA experienced disease relapses over 12 months.”

According to the news editors, the research concluded: “These results highlight the high disease burden in patients with EGPA and the need for improved treatment options.”

This research has been peer-reviewed.

For more information on this research see: Burden of Illness and Costs Associated With Eosinophilic Granulomatosis With Polyangiitis: Evidence From a Managed Care Database In the United States. Journal of Managed Care & Specialty Pharmacy, 2021;27(9):1-11. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting Christopher F. Bell, Us Med Affairs, GlaxoSmithKline PLC, Us Value Evidence & Outcomes, Res Triangle Park, NC 27709, United States. Additional authors for this research include Cori Blauer-Peterson and Jianbin Mao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18553/jmcp.2021.21002. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)